Obesity & Metabolic Health Hub

Obesity is one of the most significant and visible drivers of poor metabolic health. Excess adiposity — particularly visceral fat stored around the organs — disrupts insulin signalling, raises blood pressure, alters blood lipids, and promotes chronic low-grade inflammation. These effects place obesity at the centre of cardiometabolic risk, linking it directly to Type 2 diabetes, cardiovascular disease, stroke, and several cancers.

Obesity now affects over 1 billion people worldwide — a figure that has more than tripled since 1975 and now includes more people than those living with undernutrition in many regions. Yet BMI, the most widely used measure, captures only weight relative to height and cannot distinguish fat from muscle, or dangerous visceral fat from relatively benign subcutaneous fat. Where fat is stored matters as much as how much is carried — and measures like waist circumference and waist-to-hip ratio are increasingly recognised as stronger predictors of individual metabolic risk than BMI alone.

This hub focuses on obesity as a condition: how it is measured, how fat distribution affects risk, and why metabolic syndrome matters as a clinical concept. For a broader view of metabolic health — including GLP-1 medications, muscle preservation, and lifestyle foundations — see the Metabolic Health & Weight-Loss Medicines Hub.

How This Cluster Fits Together

This hub covers the conceptual and diagnostic layer of metabolic health — understanding what obesity is, how to measure it accurately, and what the clinical entity of metabolic syndrome means.

It connects to two adjacent hubs:

Metabolic Health & Weight-Loss Medicines Hub — covers treatment: GLP-1 medications, bariatric surgery comparisons, muscle preservation, and the broader lifestyle framework for managing metabolic dysfunction.
Diabetes Hub — covers the downstream condition: what happens when metabolic dysfunction progresses to Type 2 diabetes, and how it is managed.

The three hubs together form the complete metabolic health pathway: understanding → measurement → diagnosis → management.

Within this hub, the guides move from foundational concepts (what is obesity, what is metabolic syndrome) to practical measurement (waist-to-hip ratio, BMI limitations) to risk context (how visceral fat affects long-term outcomes).

Core Guides in This Hub

Obesity Basics

What obesity is, how it is classified, what drives it, and why framing it purely as a lifestyle problem misrepresents the biology.

Obesity Basics

Waist-to-Hip Ratio (WHR)

How to measure WHR, what the thresholds mean, and why it outperforms BMI as a predictor of individual cardiometabolic risk.

Waist-to-Hip Ratio

Metabolic Syndrome

What metabolic syndrome is, how it is diagnosed, what it means for long-term health, and what can be done about it.

Metabolic Syndrome

These guides cover the next step — what to do once metabolic risk is identified:

Ozempic and GLP-1 Weight Loss Drugs — how GLP-1 medications work and who they’re for.
GLP-1 Side Effects: Evidence vs Myth
GLP-1 vs Bariatric Surgery
GLP-1 Use in Non-Obese Adults
Muscle Preservation on GLP-1 Medications
Healthy Weight Loss Guide
Protein and Muscle Health

Why Metabolic Health Isn’t Only About Weight

Metabolic health is not determined by weight alone. Three patterns illustrate why:

Metabolically Healthy Obesity (MHO): Some people with obesity have normal blood glucose, lipids, and blood pressure. Their metabolic risk is lower than those with obesity plus metabolic syndrome — but long-term studies show MHO is often transitional, with abnormalities developing over time.

Metabolically Unhealthy Normal Weight (MUNW): People at a normal BMI can have visceral fat, insulin resistance, and elevated inflammatory markers — sometimes called TOFI (Thin Outside, Fat Inside). They carry elevated cardiovascular risk that is missed by BMI screening alone.

The limits of BMI: BMI does not account for muscle mass, bone density, fat distribution, age, sex, or ethnicity. A muscular person and a person with high visceral fat can have the same BMI. South, East, and Southeast Asian populations develop metabolic risk at lower BMI thresholds than European populations.

Waist circumference and waist-to-hip ratio tell a richer story. Metabolic markers — blood glucose, lipids, blood pressure — tell the full picture.

Frequently Asked Questions

Is BMI still a useful measure of health? BMI remains useful as a population-level screening tool but is a poor individual measure. It cannot distinguish between muscle and fat mass, does not account for fat distribution, and systematically misclassifies certain ethnic groups. Waist circumference and waist-to-hip ratio are better predictors of visceral fat accumulation and cardiometabolic risk in individuals.

What is metabolic syndrome? Metabolic syndrome is a clinical diagnosis made when a person has three or more of five criteria: elevated waist circumference, high triglycerides, low HDL cholesterol, high blood pressure, and elevated fasting blood glucose. It affects roughly 1 in 3 adults in high-income countries and substantially increases the risk of Type 2 diabetes and cardiovascular disease. See the Metabolic Syndrome guide.

How does visceral fat differ from subcutaneous fat? Subcutaneous fat sits just beneath the skin and has limited metabolic effects. Visceral fat surrounds the organs inside the abdominal cavity, releasing inflammatory cytokines and free fatty acids that drive insulin resistance and raise cardiovascular risk. Waist circumference and waist-to-hip ratio are the most accessible proxies for visceral fat accumulation.

Can I have obesity but still be metabolically healthy? Yes — “metabolically healthy obesity” (MHO) exists, but long-term studies show it is often a transitional state. Metabolic abnormalities develop over time in many who are initially healthy, and cardiovascular risk remains modestly elevated compared with normal-weight metabolically healthy individuals.

What is a healthy waist-to-hip ratio? WHO thresholds define elevated cardiometabolic risk as a WHR above 0.90 for men and above 0.85 for women. Thresholds are lower for South, East, and Southeast Asian populations. See the Waist-to-Hip Ratio guide for measurement instructions and interpretation.

How much weight loss is needed to see meaningful metabolic benefits? Even 5–7% of body weight produces clinically meaningful improvements in blood pressure, blood glucose, and lipid profiles. A 10% reduction significantly reduces visceral fat. Weight loss of 15%+ is associated with Type 2 diabetes remission and cardiovascular risk reduction comparable to medication.